Compare Biogen Inc (BIIB) vs Booking Holdings Inc (BKNG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Biogen Inc vs Booking Holdings Inc — how do they compare? Biogen Inc trades at $204.1 (market cap $30.13B), while Booking Holdings Inc trades at $212.74 (market cap $159.95B). The key difference: Booking Holdings Inc is far larger — about 5.3× Biogen Inc's market cap, and Booking Holdings Inc pays a 0.79% dividend while Biogen Inc pays none. Which is the better fit depends on your goals.
| BIIB | BKNG | |
|---|---|---|
Market Cap | $30.13B | $159.95B |
Sector | Health | Consumer Cyclical |
52-Week High | $216.63 | $228.83 |
52-Week Low | $128.93 | $154.13 |
Enterprise Value | $37.20B | $163.43B |
Dividend Yield | — | 0.79% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Biogen (BIIB) trades at $208.85, up 0.83% with bullish technical signals and strong institutional support. The company has delivered three consecutive earnings beats, with Q2 2026 EPS of $3.60 exceeding estimates by 22%. Recent acquisition of RayThera and raised 2026 guidance demonstrate strategic growth initiatives. Valuation metrics show a P/E of 36.21 and P/S of 3.01, while maintaining solid profitability with 73.99% gross margins.
Biogen presents a compelling investment case with strong earnings momentum and strategic acquisitions driving growth. However, investors face risks from declining legacy MS drug sales and net income margin compression from 16.86% in 2024 to 8.32% projected for 2026. The stock offers 12% upside to consensus price target of $234.47, supported by 62.5% analyst buy ratings.
BKNG trades at $212.26, down 0.29% on the day, with a bullish technical signal from moving averages and strong support at $212. The company reported Q2 2026 EPS of $2.54, beating estimates, and revenue growth remains robust, though net income margin dipped to 20.07% in 2025. Analyst consensus is strongly bullish with a $239.31 price target, and recent news highlights resilient travel demand and AI integration efforts.
The outlook for BKNG is positive, driven by earnings beats and solid cash flow, but risks include geopolitical volatility and high debt levels. Upside potential exists if travel demand sustains and margins improve, yet investors face headwinds from competitive pressures and economic sensitivity.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Biogen Inc
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021.
Read more on BIIB →About Booking Holdings Inc
Booking is the world's largest online travel agency by revenue, offering booking and payment services for hotel and alternative accommodation rooms, airline tickets, rental cars, restaurant reservations, cruises, experiences, and other vacation packages. The company operates a number of branded travel booking sites, including Booking.com, Agoda, OpenTable, and Rentalcars.com, and has expanded into travel media with the acquisitions of Kayak and Momondo. Transaction fees for online bookings account for the bulk of revenue and profits.
Read more on BKNG →
